SCAP and neoplasm: Moreover, the exposure to SCAP and SREBP siRNAs could block the anti-tumor and anti-lipogenesis effects of RA-XII in HepG2 cells (Figure 3 and Figure 4), suggesting that anti-tumor and anti-lipogenesis effects of RA-XII may be mediated through down-regulation of the SCAP–SREBP pathway.